Clinical Trial Update: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations [Phase 1]

View source ↗

Summary

Phase 1 study evaluating bevacizumab for acute neuromyelitis optica exacerbations; the trial completed and posted results in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 1 | Status: COMPLETED | Results posted: 2015-05-29